Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus Types 16 and 18, When Formulated With Aluminum Hydroxide, AS04, or Without Adjuvant, in Healthy Adult Female Volunteers
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
- 主要终点
- Solicited adverse event rates (including injection site and systemic reactions)
研究概览
简要总结
The goals of this study are to describe the safety, reactogenicity and immunogenicity of MEDI-517 with and without adjuvant in HPV-naïve humans. Long-term immune data is collected.
This study was originally performed by MedImmune. However, GSK is now responsible for the clinical development of the HPV vaccine.
详细描述
This is a Phase II, double-blind, randomized, comparative trial of three formulations of MEDI-517 given at 0, 30, and 180 days by intramuscular injection. The volunteers in this study will be healthy females 18 through 30 years of age. The study collects safety, reactogenicity and immunogenicity data of MEDI-517 with and without adjuvant. Extended follow-up will provide long-term immune response data.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 30 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Females 18 through 30 years of age (must not have reached the 31st birthday)
- •Written informed consent obtained from the volunteer
- •Unless previously surgically sterilized, agrees to use an effective method of birth control beginning 30 days before the first study injection and continuing through 60 days after the final study injection
- •Must have a negative serum pregnancy test within 21 days of study entry and must not be breast feeding
- •Healthy by medical history and physical examination
- •Seronegative for HPV-16 and HPV-18 antibody by ELISA within 21 days of study entry
- •Cervical specimen negative for high-risk HPV DNA using the Digene Hybrid Capture® II HPV test (high-risk types Probe B) within 21 days of study entry
- •Normal Pap smear, using the Cytyc ThinPrep® Pap Test, within 21 days of study entry
- •No evidence of anogenital HPV lesions or physical findings suggestive of other gynaecologic pathogens on pelvic examination within 21 days of study entry
- •Agrees to no other vaccines or experimental therapy until 30 days after the last study injection
排除标准
- •Acute illness or fever (oral temperature ≥ 99.5°F [37.5°C]) at start of the study
- •History or clinical manifestations of significant medical or psychiatric disorder
- •Use of immunosuppressive medication (inhaled and topical corticosteroids are permitted) within the previous 90 days or history of immunodeficiency
- •History of cancer
- •History of alcohol or drug abuse within the past 2 years
- •Abnormal laboratory blood values at screening. Other abnormal laboratory values in the screening panel which in the opinion of the principal investigator are judged to be clinically significant
- •Receipt of immunoglobulin or blood products within 90 days prior to study entry
- •History of abnormal Pap smear (other than a single prior report of ASCUS or indeterminate Pap smear with a subsequent normal report)
- •Genital herpes disease involving the cervix or with disease characterized on examination or by history by extensive external lesions. Volunteers with a history of recurrent genital herpes disease characterized by limited external lesions are eligible to participate in the study.
- •Positive tests for hepatitis C antibody, hepatitis B surface antigen, or HIV-1 antibody
- •Any prior receipt of any vaccine (experimental or otherwise) for treatment or prophylaxis of genital warts or other papillomavirus related condition. Any treatment of genital warts or other papillomavirus related condition within 6 months of randomization (local therapy for common skin and/or plantar warts is allowed)
- •Previous administration of any components of the investigational vaccine
- •Receipt of any experimental vaccine within 90 days prior to entry into this study
- •Receipt of any experimental drug therapy within 30 days or five half-lives of the experimental drug (if the half-life is known), whichever is longer
结局指标
主要结局
Solicited adverse event rates (including injection site and systemic reactions)
时间窗: For 7 days after each injection
Solicited adverse event rates
时间窗: For 30 days after each injection
Vital signs (temperature, blood pressure, pulse rate, respiratory rate)
时间窗: At the time of each injection and 30 minutes after each injection
Laboratory assessments (Chemistry and Hematology parameters)
时间窗: Study Days 0, 30 and 210
Serious adverse event rates
时间窗: From first injection through 6 months after last injection
Serum ELISA titers against HPV-16 and HPV-18
时间窗: 30 days after the third injection
次要结局
- Serum ELISA titers against HPV-16 and HPV-18(Study Days 0, 7, 30, 60, 180, 210, and 360, and at 18, 24, 36, and 48 months)
- Lymphoproliferative, IL-5, and IFN-γ assays(Study Days 0, 60, 210, and 360, and at 18, and 24 months)
- Inhibitory ELISAs(Study Days 0, 60, 210, and 360, and at 18, 24, 36, and 48 months)
- Neutralization titers against HPV-16 and HPV-18(Study Days 0, 60, 210 and 360)